Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, firstly discusses the results from two trials; IMpassion130 (NCT02425891) and IMpassion131 (NCT03125902). The IMpassion130 investigates the use of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated metastatic triple-negative breast cancer (TNBC) patients. The IMpassion131 trial investigates the use of atezolizumab and paclitaxel vs placebo plus paclitaxel in previously untreated locally advanced or TNBC patients. IMpassion130 showed a positive overall survival (OS). Secondly, Dr. Bardia discusses the results from the SOLAR-1 trial (NCT02437318). The SOLAR-1 trial investigated the use of alpelisib plus fulvestrant vs placebo plus fulvestrant in men and postmenopausal women which progress on or after aromatase inhibitor treatment. Additionally, Dr. Bardia also discusses the monarchE trial (NCT03155997) and the PALLAS trial (NCT02513394). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).